China thinks big on brain-computer interfaces after world-first surgery

China's first commercial BCI surgery, performed last month, is a concrete step in the global neurotechnology race. This is not just a medical breakthrough; it is a clear statement of intent from Beijing to lead in a critical emerging technology. The subsequent launch of a BCI insurance policy by state-owned PICC Property and Casualty shows a rapid move from clinical trial to commercial readiness and regulatory support within China. Our view is that this dual development points to a state-backed push to integrate BCI technology into the healthcare system, potentially creating a significant domestic market. The thing to watch is how quickly this commercialization scales and whether it leads to broader adoption across Asia. While the US has prominent private players like Neuralink, China's state-backed approach could accelerate development and deployment, especially in areas with high medical need.